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In the course of a clinical trial consisting of intratumoral injec-
tions of dendritic cells (DCs) transfected to produce interleukin-
12, the use of 111In-labeled tracing doses of DCs showed that most
DCs remained inside tumor tissue, instead of migrating out. In
search for factors that could explain this retention, it was found
that tumors from patients suffering hepatocellular carcinoma, col-
orectal or pancreatic cancer were producing IL-8 and that this
chemokine attracted monocyte-derived dendritic cells that uni-
formly express both IL-8 receptors CXCR1 and CXCR2. Accord-
ingly, neutralizing antihuman IL-8 monoclonal antibodies blocked
the chemotactic attraction of DCs by recombinant IL-8, as well as
by the serum of the patients or culture supernatants of human col-
orectal carcinomas. In addition, tissue culture supernatants of
colon carcinoma cells inhibited DC migration induced by MIP-3b
in an IL-8-dependent fashion. IL-8 production in malignant tissue
and the responsiveness of DCs to IL-8 are a likely explanation of
the clinical images, which suggest retention of DCs inside human
malignant lesions. Impairment of DC migration toward lymphoid
tissue could be involved in cancer immune evasion.
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Malignant cells or tumor stroma produce cytokines that not only
tamper with immunity, but also regulate other functions such as
angiogenesis, invasiveness, metastasis and cell growth.1 It seems
that tumors kidnap normal systems of intercellular communication
to support their own growth and spread. IL-8 is an ELRþ-CXC
chemokine identiﬁed for its potent chemotactic activity on human
granulocytes.2 CXCR1 is quite speciﬁc for IL-8, while CXCR2 is
a common receptor for many other ELRþ-CXC chemokines.3
Mice do not express a homologous IL-8 molecule, thus preventing
deﬁnitive experimentation in these animal models, but MIP-2 and
KC chemokines bind to CXCR1 and mediate neutrophil chemo-
taxis in murine models.4
Human tumors from most tissue origins have been found to pro-
duce IL-8 in fairly large quantity,5 probably reﬂecting the broad
capability of normal cells to produce IL-8 under proinﬂammatory
stress.6 Mechanisms controlling mRNA transcription and DNA
methylation are probably critically involved in derepressing IL-8
in tumors,5,7 and it has been shown that IL-8 plays a signiﬁcant
role in tumor angiogenesis and metastasis.3,5 The detailed molecu-
lar mechanisms underlying such activities are complex, but direct
chemotactic effects on endothelial cells have been described.8
Artiﬁcial transfections support the relevance of IL-8 in these
pathogenic mechanisms of cancer. However, most genetic experi-
ments have been performed in immunodeﬁcient mice able to graft
human carcinomas.5 Therefore, it is unknown whether tumor-
derived IL-8 could interfere with antitumor immunity.
Vaccine formulations based on dendritic cells (DCs) loaded
with different sources of tumor antigens are being tested in clinical
trials.9,10 Although increases in antitumor-speciﬁc immunity are
frequently reported,11 efﬁcacy has not yet matched those seen in
mouse models. When DCs are artiﬁcially released intratumorally,
they can pick up antigens from the environment,12 migrate to lym-
phoid tissues and present antigens to T cells.12–15
The antitumor activity of this strategy has been further
enhanced by the transfection of IL-12 genes into the DCs.12,13 A
phase 1 clinical trial is being performed in our institution to assess
safety and efﬁcacy of intratumoral injection of IL-12-transfected
DCs in advanced cancer patients. During the trial, we observed
that IL-12-producing DCs injected into tumor nodules migrated
very poorly out of the lesions. It was found that all patients
included in the trial had high serum concentrations of IL-8 and
that this chemokine attracts monocyte-derived DCs.
Material and methods
Patients
Fifteen patients with advanced metastatic digestive carcinomas
originating from liver (n ¼ 7), pancreas (n ¼ 3), or colon (n ¼ 5)
were included in the study approved by the Spanish Medicine
Agency (IL-12/00/002).
Autologous, immature and mature DCs were transfected with
adenovirus expressing IL-12 genes (AFIL-12) and administered to
patients by ultrasound-guided intratumoral injections. Three
cohorts of 5 patients received 3 doses of 107, 2.5  107, or 5  107
transfected DCs at 21-day intervals. Detailed description of the
clinical safety, efﬁcacy and biologic effects will be reported on
completion of this clinical study.17
Dendritic cell generation
Dendritic cells were generated from buffy coat-derived mono-
cytes donated by healthy donors or from cancer patient leukaphe-
resis products. Isolated mononuclear cells from these sources were
subjected to positive selection using anti-CD14-conjugated para-
magnetic beads and puriﬁed using the AutoMACSs and Clini-
MACs systems (Miltenyi Biotec, Bergisch Gladbach, Germany).
Puriﬁed monocytes were cultured for 7 days in AIM-V serum-free
media (Gibco-BRL, Gaithersburg, MD) supplemented with GM-
CSF (1000 U/ml; Novartis, Basel, Switzerland) and IL-4 (500 U/
ml; R&D Systems, Minneapolis, MN). Fresh cytokines were
added every two days to the differentiation cultures. DCs were
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matured with clinical grade TNF- (50 ng/ml; Boehringer Ingel-
heim, Ingelheim, Germany), IFN- (1,000 IU/ml; Schering-
Plough, Kenilworth, NJ) and PGE2 (20 g/ml; Pharmacia, Kala-
mozoo, MI) for 24 hr.
111In labeling and imaging
Just before labeling, 1 mL of 111In-oxinate (Mallinkrodt
Medical, St. Louis, MO) was diluted with 0.4 mL of 0.1 M tris-
HCl buffer (pH 7.2). AF-IL12-transfected DCs (5  106) were
labeled with 100–400 Ci of 111In-oxinate for 20 min at room
temperature with occasional gentle shaking. After incubation, cells
were washed 3 times and resuspended in saline. Cells were mixed
with the nonlabeled DCs to complete the dose and were injected
intratumorally. Scintigraphic images were acquired with a double-
headed gamma camera (E CAM; Siemens, Erlangen, Germany).
Cell lines and IL-8 concentrations in sera and culture
supernatants
HT29, Caco2, SW48, HepG2 and ASPC-1 cell lines were
obtained from American Type Culture Collection (Rockville,
MD). The concentration of IL-8 in supernatants from these cell
lines, DCs and serum samples was determined by ELISA (BD
Biosciences, San Diego, CA).
Immunoﬂuorescence, FACS analysis and Western blot
Before immune staining, cells were incubated with PBS/human
IgG (50 g/ml; Beriglobina P; Aventis, King of Prussia, PA) for
20 min on ice to block Fc receptors. Subsequently, DCs were incu-
bated with mAbs anti-CXCR1 and -CXCR2 (R&D Systems) or
isotype-matched antibodies followed by an FITC-conjugated sec-
ondary antibody (Dako, Glostrup, Denmark). Samples were ana-
lyzed using a FACSCalibur ﬂow cytometer (BD Biosciences). For
Western blot experiments,16 mature and immature DCs as well as
neutrophils from healthy donors were lysed in ice-cold Cellytic-M
Mammalian Cell Lysis buffer (Sigma, St. Louis, MO), to which 5
g/ml of leupeptin and aprotinin (Sigma) were added. Proteins (30
g) were separated by 10% SDS-PAGE (Bio-Rad, Richmond,
CA) and blotted onto nitrocellulose membranes. Blots were proc-
essed as previously described16 with anti-CXCR1 and anti-
CXCR2 antibodies (2 g/ml; Serotec, Dusseldorf, Germany)
and visualized by chemiluminiscence (Amersham Pharmacia,
Uppsala, Sweden).
Chemotaxis assays in vitro
In vitro DCs migration was measured in Transwell Chambers
(8 m; Corning Costar, Corning, NY). Mature DCs (4  105) were
cultured in the upper chambers and migration was assessed after
16 hr of culture at 378C. The following migration stimuli were
used in the lower chamber: MIP-3 (R&D Systems), human
recombinant IL-8 (R&D Systems), different dilutions (1/2, 1/5 and
1/10) of HT29, Caco2 and SW48 supernatants collected from 80%
conﬂuent cultures and serum samples (5%, 10% and 50% v/v).
When indicated, an antihuman IL-8 antibody (BD Pharmingen,
San Jose, CA), which neutralizes IL-8 activity or control antibody,
was added at 5 g/ml to the lower chamber. Transmigrated cells
in the lower chamber were quantiﬁed by counting them under
microscopy using Neubauer chambers. Chemotactic index was
calculated as number of migrated cells in the experimental condi-
tions divided by number of migrated cells in the negative control
(culture medium).
HT29 cell supernatant was also tested for its capacity to neutral-
ize DC migration induced by MIP-3 (R&D Systems) in transwell
chambers. In these experiments, DCs (4  105) were resuspended
in HT29 supernatant with anti-IL8 mAb or control antibody (BD
Biosciences) and added to the upper chambers while different con-
centrations of MIP-3 (0.1, 1, 10 and 100 ng/ml) were added to
the lower chambers.
Results
DCs injected intratumorally fail to migrate out of human
carcinomas
A clinical trial consisting of 3 intratumoral doses of monocyte-
derived DCs adenovirally transfected to produce IL-12 is ongoing
at our institution (IL-12/00/002). The clinical trial has included
treatment of 17 patients suffering digestive cancers without toxic-
ity. Evidence for biologic activity was detected in most patients
with 2 cases of disease stabilization and 1 objective partial
response.17 In a series of 5 patients of this clinical trial, who have
received 3 doses of 5  107 of such monocyte-derived DCs at 3
weekly intervals, 5  106 cells (10% of the total dose) were
labeled with 111In-oxinate. This technique is routinely used to
trace adoptively transferred neutrophils and platelets for various
clinical purposes. After ultrasound-guided administration of DCs,
patients were scanned under a high-resolution gamma camera.
This technique has been previously used by other authors to moni-
tor migration of DCs after subcutaneous or intravenous injection
during vaccination protocols for melanoma treatment.18
Patient 1 (Fig. 1) with metastatic colon cancer received IL-12-
transduced immature DCs inside a liver metastasis. Patient 2, who
suffered from metastatic cholangiocarcinoma, received a similar
treatment to a bone metastasis, although in this case DCs were cul-
tured during the last 24 hr before injection in the presence of clini-
cal grade TNF-, IFN- and PGE2. Maturation was monitored by
assessing surface expression of CD80, CD83, CD86, HLA-DR
and CCR7 (data not shown).
111In biodistribution in these patients was observed in scinti-
gram images taken 30 min, 24 hr and 48 hr after injection (Fig. 1).
In patient 1, most of the dose remained intratumorally 15–30 min
after injection, while a small fraction reached the lungs, presum-
ably through vascular dissemination. Twenty-four and 48 hr later,
most of the dose still remained intratumoral, while the intravascu-
larly escaped DCs reached the spleen. Some other organs such as
liver and bone marrow can be faintly visualized. This is consistent
with a previous report showing that intravenously infused DCs
were found ﬁrst in lungs and later in the spleen and liver.18
Since immature DCs fail to express chemokine receptors guid-
ing them to secondary lymphoid organs, we thought that providing
a 24-hr maturation culture would help DCs to reach draining
lymph nodes by inducing CCR7 expression.19 However, as it can
be seen in Figure 1, when mature DCs were used (patient 2), as
with the immature DCs of patient 1, injected cells were retained
inside the treated scapular metastasis. Again, part of the dose
injected escaped to the lungs through the blood stream immedi-
ately after injection. Most of the remaining dose stayed inside the
injected lesion for 24 and 48 hr (Fig. 1). Similar observations have
been made in the other 3 patients with intrahepatic masses of pan-
creatic cancer, colon cancer and hepatocellular carcinoma (data
not shown).
IL-8 is secreted by digestive carcinomas reaching high
serum concentrations
It has been described in a number of reports that human malig-
nancies, including colon adenocarcinomas, pancreatic cancer and
primary liver cancer, produce and secrete IL-8.5 Therefore, IL-8
could be a candidate molecule to mediate a chemotactic retention
of DCs inside tumor tissue. To explore this possibility, IL-8 con-
centration was measured in serum samples from all patients
included in the clinical trial. In these cases, IL-8 was detectable at
concentrations between 19 and 601 pg/ml, whereas IL-8 was
under the limit of detection (12 pg/ml) in all 15 control serum
samples from healthy volunteers (p < 0.001; Fig. 2a). To conﬁrm
that IL-8 is secreted by human malignant cells, we examined IL-8
concentrations in tissue culture supernatants of 3 colon carcinoma
cell lines (HT29, Caco2 and SW48), 1 hepatocellular carcinoma
cell line (HepG2) and 1 pancreatic adenocarcinoma cell line
(ASPC-1). IL-8 concentrations in tissue culture supernatants
from HT29, Caco2, ASPC-1 and HepG2 cell lines were high
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(50–200 pg/ml). However, SW48 colon carcinoma cell line did
not produce detectable IL-8 (Fig. 2b), indicating that IL-8 produc-
tion is a frequent but not constant feature of these types of cancer.
DCs are responsive to IL-8
If IL-8 is a factor directly involved in retaining DCs inside
malignancies, DCs should express functional receptors for this
chemokine on their plasma membrane. Previous studies had docu-
mented that CXCR1 is expressed by DCs as detected by Northern
blot and ﬂow cytometry.19,20
We were able to conﬁrm that DCs expressed CXCR1 and in
addition found coexpression of CXCR2 (Fig. 3a). Moreover, a
decrease of CXCR1 expression was detected after maturation
induced by TNF-, IFN- and PGE2 (Fig. 3a), consistent with a
previous report showing that CXCR1 expression is downregulated
in the presence of LPS.19
Next, bands showing a molecular weight of 39 kDa were clearly
detected by immunoblotting with antibodies to CXCR1 and
CXCR2 in DCs and granulocyte lysates (Fig. 3b). In addition to
the 39 kDa band described in neutrophils, we found a further, less
intense band of approximately 50 kDa. The identity of this addi-
FIGURE 1 – Intratumorally injected DCs migrate poorly out of human malignant lesions regardless of their maturation status. Sequential gam-
magraphic follow-up of 2 patients after ultrasound-guided injection of 5  107 DCs transfected to produce IL-12 by means of recombinant
adenovirus (AFIL-12). Ten percent of the dose (5  106 DCs) was labeled with 111In-oxynate. Images were taken during the ﬁrst hour and 24 hr
and 48 hr after injection as indicated. Patient 1 received immature DCs, while patient 2 received mature DCs.
FIGURE 2 – IL-8 is secreted by digestive carcinomas. (a) IL-8 serum
concentrations were measured by ELISA in 15 patients with digestive
carcinomas and in 15 healthy controls. p was calculated with a Mann-
Whitney U-test. (b) Production of IL-8 by human pancreatic (ASPC-
1), hepatocellular (HepG2) and colon (CaCo2, HT29 and SW48) car-
cinoma cells. Culture supernatants were harvested from 105 cells after
24 hr of incubation and IL-8 content was measured by ELISA. Results
representative of 3 independent experiments are shown as mean 6 SD
of triplicate cultures.
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tional molecule reactive with the anti-CXCR1 and anti-CXCR2
mAbs is being currently explored, since it is undetectable in neu-
trophils and may be speciﬁc to DCs. Differentially regulated
mRNA splicing is a possibility that has been recently reported for
CXCR3.21
Both immature and mature DCs were found to produce IL-8
into the supernatant during tissue culture (Fig. 3c), suggesting that
IL-8 could act in an autocrine or paracrine fashion. The role of IL-
8 secreted by DCs at either maturation stage remains elusive,
although increases during maturation (Fig. 3c) are probably
involved in sustaining inﬂammation.22 In the case of intratumor-
ally injected DCs, production of IL-8 by the DCs themselves may
contribute to their poor migration out of malignant tissue.
In our hands, expression of both CXCR1 and CXCR2 receptors
correlated with the response of DCs to human recombinant IL-8
protein in a wide range of doses as detected in classic transwell
migration assays (Fig. 4a). The ability of such recombinant pro-
tein to attract DCs was blocked with neutralizing mAb (Fig. 4a).
Moreover, tissue culture supernatants of human colorectal carci-
noma cell lines (HT29 and Caco2) attracted DCs in a fashion that
was also inhibited by antihuman IL-8 mAb (Fig. 4b). Supernatants
from SW48 cell line in which IL-8 had not been detectable failed
to attract DCs (Figs. 2b and 4b). Most importantly, serum samples
from the patients included in the clinical trial also attracted DCs in
a mode dependent on IL-8 (Fig. 4c). A previous study has sug-
gested that CXCR1 and CXCR2 were nonfunctional in DCs
derived in culture with GM-CSF and IL-13 in spite of detectable
expression of the receptors.23 Reasons for the discrepancy
between these data and our own might involve differentiation con-
ditions of DCs in culture.
Tumor cells can prevent DCs migrating out of malignant lesions
by producing IL-8
If IL-8 secretion by carcinoma cells is a factor in the poor
migration of injected DCs out of tumors, IL-8 should oppose the
attraction of DCs by other chemokines produced beyond the can-
cer. The main chemokines guiding DCs from peripheral, i.e.,
tumor tissue, to secondary lymphoid organs are the CCR7 ligands,
MIP-3 (ELC) and 6-C-kine (SLC).24 We found that DCs can be
retained by supernatants of colon cancer cells diminishing their
response to MIP-3 in classical chemotaxis assays (Fig. 5). This
effect was neutralized by anti-IL-8-speciﬁc mAb and could be
overcome by higher concentrations of MIP-3. Such in vitro
experiments resemble the situation of tumors producing IL-8 that
retain DCs, in such a way that DCs would not respond to chemo-
kines guiding them to lymphoid organs.
Discussion
In the overall effort of clinical research to explore the potential
of DCs to elicit antitumor immunity,25 this study deﬁnes an unex-
pected limiting factor for the intratumoral route of DC administra-
tion consisting of a poor migration of DCs into lymphoid tissue.
Intratumoral injection of DCs as a cancer treatment relies on sev-
eral steps that take place once DCs are released inside the organ-
FIGURE 3 – Human dendritic cells express CXCR1 and CXCR2 and
produce IL-8. (a) Surface expression of CXCR1 and CXCR2 on
immature (iDCs) and mature (mDCs) dendritic cells were assessed by
ﬂow cytometry. Filled histograms represent cells stained with the iso-
type control antibody, whereas open histograms correspond to cells
stained with anti-CXCR1 or -CXCR2 mAbs as indicated. (b) Western
blot analysis of CXCR1 and CXCR2 expression in iDCs and mDCs.
Blots were probed with mouse anti-CXCR1 and anti-CXCR2 mAbs.
Cell lysates from human myoblasts (Neg) and neutrophils (NP) were
respectively included as negative and positive controls. (c) IL-8 con-
centrations (mean 6 SD) were measured by ELISA in 24-hr culture
supernatants of immature and mature DCs (105 /ml).
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ism: antigen capture from malignant cells,26 migration into lymph
nodes13,27 and antigen presentation by activated DCs to T
cells.13,27,28 In mouse models, intratumoral injections of DCs can
eradicate several transplanted tumors when DCs are pretransfected
with genes encoding IL-12,12,13 IL-7,15 or CD40L.14 In the case of
IL-7, there is therapeutic evidence even in lung cancer arising in
mice transgenic for an oncogene after being peritumorally injected
with DCs engineered to produce IL-7.29 In this regard, we have
experimental evidence showing that intratumoral DCs transfected
to produce IL-15 induce curative immunity in some mouse tumor
models (data not shown). Even untransfected immature DCs when
injected inside tumor tissue can induce systemic antitumor
immunity that controls micrometastasis but not the primary
tumor.30 Thus, experimentation in rodents clearly suggests that the
intratumoral route of administration had potential for translational
research with DC-based immunotherapy. In these mouse models,
DC migration from malignant to lymphoid tissue seems not to be
a problem. DCs labeled with the GFP gene or ﬂuorochromes reach
the interfollicular areas of lymph nodes quite efﬁciently.13,27,31
Preclinical efﬁcacy in rodents prompted clinical development
of intratumoral injection of DCs that had been engineered to pro-
duce IL-12. In our studies in human patients harboring digestive
carcinomas, deﬁcient migration seems to be an important issue.
Intratumoral retention was observed in scintigrams taken after
intratumoral administration of tracing doses of 111In-labeled DCs
either with immature DCs or with DCs that had been matured with
TNF-, IFN- and PGE2. It is noteworthy that maturation under
these stimuli promoted CCR7 expression and responsiveness to
lymph node-homing chemokines (data not shown). Although more
potent maturation-inducing agents such as Toll-like receptor ago-
nists were considered, they were not included because clinical-
grade products were not available. In this regard, adenovirus trans-
fection of DCs is known to induce partial maturation of the
cells32,33 and IL-12 acting on a variant of the IL-12 receptor
expressed by DCs enhances the maturation program.34 As a result,
DCs transfected with the IL-12-encoding adenovirus should expe-
rience an additional set of activation/maturation signals dependent
on the virus and on the autocrine effects of IL-12.
The sequential scintigrams performed to the patients cannot
completely disregard that a minority of DCs could have reached
draining lymph nodes. Moreover, part of the DCs reaching the
spleen could have stayed long enough inside the tumor mass as to
be loaded with tumor antigens. Nonetheless, with these clinical
images in mind, we found that the serum of all patients in the clin-
ical study contained signiﬁcant quantities of the IL-8 chemokine.
Several reports had demonstrated that IL-8 was secreted by malig-
nant cells in human digestive carcinomas,5,35–37 while genetic evi-
dence in mice indicated a role for IL-8 in angiogenesis and
metastasis. We thought that the chemotactic activity of IL-8, pre-
viously characterized on polymorphonuclear leukocytes (PMNs),6
monocytes23 and endothelial cells,8 could be involved in intratu-
moral retention of DCs, provided that DCs would respond to IL-8.
The IL-8 receptor CXCR-1 had been found on DCs in previous
studies,19,20,23 but somehow DCs differentiated from monocytes
with GM-CSF and IL-13 were not chemoattracted by IL-8 in spite
of receptor expression.23 In our hands, both IL-8 receptors CXCR-
1 and CXCR-2 are expressed on DCs differentiated with GM-CSF
and IL-4 from CD14þ immunomagnetically puriﬁed monocytes in
FIGURE 4 – Human DCs are chemoattracted by IL-8 secreted by
tumor cells. Migration DCs in transwell migration assays. In these
experiments, DCs (4  105) were set across 8 m pore transwells
exposed to (a) different concentrations of recombinant human IL-8,
(b) HT29, Caco2 and SW48 culture cell supernatants (10% v/v) and
(c) serum from a patient (5% v/v) containing 30 pg/ml of IL-8. When
indicated, a neutralizing antihuman IL-8 antibody or control mouse
IgG mAb were added. Migration is expressed as chemotactic index
(mean 6 SD).
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serum-free media. Importantly, these DCs are attracted by IL-8.
This apparent discrepancy can probably be reconciled if the differ-
entiation conditions are taken into account and it raises interesting
points on the existence of nonfunctional CXCR-1 receptors under
certain conditions. Indeed, all these studies have been performed
on ex vivo differentiated DCs and it would be interesting to know
what is the case with DCs isolated from human tissues that are the
relevant ones in the physiology of the immune system.
The ﬁnding that IL-8 can attract DCs might be relevant for DCs
recruitment into inﬂamed tissue or for DC-endothelium cross-
talk.38 During inﬂammation, IL-8 can be involved in colocalizing
PMN leukocytes and professional antigen presenting cells at the
microbial entry site. There are lines of research that indicate an
important function for this rendezvous of leukocytes at the initia-
tion of adaptive immunity in inﬂammatory foci.10 It seems wise
for DCs to reach tissues containing a likely source of dangerous
antigens, requiring eventual presentation to the immune system.
It is noteworthy that, in spite of the production of IL-8 in tumor
tissue, there is not a massive inﬁltrate of neutrophils inside most
malignancies. This probably reﬂects the fact that leukocyte extrav-
asation needs adherent proinﬂammatory vascular endothelium in
addition to the IL-8 chemotactic signal.39
Apart from migration, we have not found effects of IL-8 on
other functions of DCs. Maturation is not modiﬁed in our hands
by IL-8, at least up to 100 ng/ml. Exposure to IL-8 neither changes
the basal level of surface expression of CD86, MHC-II and CD83
on immature DCs, nor the level of maturation induced with
TNF-, IFN- and PGE2 (data not shown). In addition, similar
concentrations of IL-8 do not change the MLR-stimulating activ-
ity of these DCs (data not shown). We have also found that IL-8 at
4 ng/ml did not decrease expression levels of CXCR1 and CXCR2
(data not shown), thus indicating that IL-8 does not desensitize
DC to itself. However, it has been shown that IL-8 activates neu-
trophil functions other than migration, such as the respiratory
burst,40 thus suggesting that IL-8 could modulate other matura-
tion-unrelated functions of DCs.
This study provides strong in vitro evidence that IL-8 can che-
motactically retain DCs and therefore this molecule is a good can-
didate to mediate sequestration of DCs inside human tumors, at
least in the patients included in this trial.
Chemokine retention of DCs inside the malignancies could be a
major factor for the weakness of the immune responses elicited in
the trial. Other factors potentially downsizing the efﬁcacy of the
intratumoral route, at least in digestive carcinomas, are the local
production of TGF- and VEGF that can downregulate DC func-
tions by means of preventing maturation/activation of these
cells.41,42 It is important to mention that IL-8 might not be the
only factor involved in DC retention inside the tumor. Other possi-
bilities include the poor lymphatic vessel drainage of malignant
tissue, the impairment of the natural pathways of DC circulation
and the possible interplay of other factors with chemotactic activ-
ity on DCs. Tumors seem to have learned how to exploit the
attraction/retention of leukocytes actively, as recently shown for
regulatory T cells43 and for DCs.44 Interestingly, at least in certain
models, local VEGF at the tumor mass seems to subvert the differ-
entiation of the attracted/retained DCs toward endothelial lineage,
while turning them into tolerogenic antigen presenting cells.44
It would be interesting to study whether IL-8 secretion by
malignant cells could tamper with endogenous DCs and therefore
provide tumors with immune escape mechanisms. It is noteworthy
that IL-8 tumor transfectants have been studied in animals devoid
of adaptative immune systems and therefore immune-interfering
properties of IL-8 could have been overlooked. The lack of IL-8
in the mouse genome has been an important limiting factor in this
regard.45
As a whole, our ﬁndings have direct implications for explaining
the active retention of DCs injected intratumorally with an immu-
notherapeutic aim. It is possible that IL-8 might also be involved
in retaining endogenous DCs inside malignancies. In either case,
deﬁcient migration into lymphoid tissue could be preventing efﬁ-
cacious cross-priming of tumor antigens.26,46,47
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